Can Botox Ease Chronic Pelvic Pain?
-
By
November 14, 2024
-
3 min
-
1
Only 33% of women receiving Botulinum Toxin A injections for chronic pelvic pain experienced a 33% reduction in pain scores compared to 20% receiving placebo.
-
2
The study included 94 women who had previously undergone pelvic floor muscle therapy without adequate improvement.
-
3
Both groups showed similar rates of perceived improvement, with 17% reporting substantial improvement in each group.
-
4
The findings do not support the use of BTA injections in the management of chronic pelvic pain in women.
-
5
Adverse events were generally mild, with immediate post-treatment bleeding occurring in 4% of both groups.
-
6
Constipation occurred in 6% of the BTA group versus 0% in the placebo group.
-
7
The study faced limitations due to the COVID-19 pandemic, further research could identify patient subgroups that may respond to BTA treatment.
-
A recent double-blind, randomized controlled trial assessed the efficacy of Botulinum Toxin A injections in conjunction with pelvic floor muscle therapy for women with chronic pelvic pain and high pelvic floor muscle tone. The study revealed that only 33% of women receiving Botulinum Toxin A injections experienced a 33% reduction in pain scores compared to 20% receiving placebo. While the BTA group demonstrated a significant reduction in pelvic floor resting muscle activity, this did not correlate with a significant reduction in pain intensity or improvement in quality-of-life metrics, leading to the conclusion that the findings do not support the use of BTA injections in the management of CPP in women.
-
1
Only 33% of women receiving Botulinum Toxin A injections for chronic pelvic pain experienced a 33% reduction in pain scores compared to 20% receiving placebo.
-
2
The study included 94 women who had previously undergone pelvic floor muscle therapy without adequate improvement.
-
3
Both groups showed similar rates of perceived improvement, with 17% reporting substantial improvement in each group.
-
4
The findings do not support the use of BTA injections in the management of chronic pelvic pain in women.
-
5
Adverse events were generally mild, with immediate post-treatment bleeding occurring in 4% of both groups.
-
6
Constipation occurred in 6% of the BTA group versus 0% in the placebo group.
-
7
The study faced limitations due to the COVID-19 pandemic, further research could identify patient subgroups that may respond to BTA treatment.
Listen Tab content
